
About
BioDlink is a CDMO specializing in biologics and bioconjugates, including ADCs/XDCs, with headquarters in Suzhou and centers in Shanghai and Beijing. It provides end-to-end services from early R&D through commercial manufacturing for global clients.
Services
ADC R&D Service Platform
Provides one-stop ADC R&D sample preparation and druggability study services from molecular screening to preclinical candidate compound stage.
ADC R&D Service Platform analysis
Offers tailored analysis and testing services for ADC molecules, including DAR, purity, free drug, concentration, and endotoxin testing.
ADC Process Development and Optimization
Develops and optimizes conjugation processes for ADCs and related bioconjugates.
Drug Product Formulation and Lyophilization
Develops drug product formulations and lyophilization processes for ADC and protein/antibody programs.
Analysis Services
Provides analytical method development, validation, transfer, release testing, stability, structural characterization, and biosimilarity/comparability studies for biologics and ADCs.
Antibody Manufacturing
Manufactures antibody drug substance and drug products at commercial scale.
CDMO: development & manufacturing
ADC Drug Substance Manufacturing
Manufactures ADC drug substance at commercial scale.
CDMO: development & manufacturing
Lyophilized Drug Product Manufacture
Manufactures lyophilized ADC and antibody drug products.
CDMO: development & manufacturing
8 more services
- Protein/Antibody Platform
- Cell Culture Process Development
- Purification Process Development
- GMP Manufacturing
- Technology Transfer
- Quality Control
- Quality Assurance
- Regulatory Affairs
- Turnaround
- 1-3 weeks
- 2-5 weeks
- One Week TAT for the marketed product conjugation types
- What to send
- Tel
- Sample Preparation Quantity
- Conjugation Method
- DAR Value
- Large Molecular Type
- Small Molecule Type
- Estimated Demand Time
Capabilities
- Assays and studies
- ADCs
- Antibodies
- Process development
- Lyophilization
- Analytical development
- Small molecules
19 more
- Bispecifics
- HPLC
- LC-MS/MS
- Peptides
- DAR (RP-HPLC, HIC-HPLC, LC-MS)
- Purity (SEC)
- Free drug (RP-HPLC)
- Concentration (UV)
- Endotoxin
- Cell-based activity assay
- Structural characterization
- Higher order structure analysis
- Charge variants analysis
- Biosimilar similarity study
- Comparability study
- ADCC
- CDC
- ADCP
- Reporter gene assay
- Scale and capacity
- Total manufacturing capacity exceeded 20,000 L
- 200 L bioreactors
- 500 L bioreactors
- 2,000 L bioreactors
- Four commercial manufacturing lines
- Large-scale sterile fill-finish capabilities
Instruments and platforms
- RP-HPLC
- HIC-HPLC
- LC-MS
- SEC
- UV
- CE-SDS
9 more
- IEC
- iCIEF
- CZE
- SPR
- BLI
- CD
- DSC
- SEC-MALS
- AUC
Modalities and species
- Modalities
- Small molecule
- Antibody
- Bispecific
- ADC
- Peptide
- Recombinant protein
- Biosimilar
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2010
- Office
- 120 Changyang Street,Suzhou Industrial Park,Suzhou, PRC
- Sites
- Suzhou, China
- Shanghai, China
- Beijing, China
- Serves
- China, Indonesia, Nigeria, Pakistan, Colombia, Bolivia, Japan